Overview

Personalized mRNA cancer vaccines represent a paradigm shift in oncology, encoding tumor-specific antigens to engage the patient's own immune system. To realize this promise, researchers need mRNA that is not only sequence-accurate but also optimized for translational efficiency and immune activation.

mRNA production for cancer immunotherapy begins with in vitro transcription from a DNA template, followed by capping and poly(A) tail addition to enhance stability and translation. The resulting mRNA can encode tumor antigens, immunomodulators, or bispecific antibodies, and must be delivered in a formulation that ensures efficient uptake by antigen-presenting cells or T cells. Our service covers the entire workflow—from template design to GMP-grade manufacturing—enabling you to focus on therapeutic efficacy rather than production logistics.

We leverage next-generation sequencing (NGS) to identify patient-specific neoepitopes and design mRNA constructs that match the tumor's genetic signature. This personalized approach, combined with scalable manufacturing and rigorous quality control, supports the rapid development of cancer vaccines that are both safe and effective. Our team has deep expertise in RNA chemistry, lipid nanoparticle (LNP) engineering, and tumor immunology, ensuring that your mRNA candidate meets the highest standards for preclinical and clinical trials.

Whether you are developing a first-in-human personalized vaccine or a multi-antigen immunomodulator, our mRNA production platform delivers the consistency and functionality required for success. From small-scale research batches to GMP-grade clinical supply, we provide full documentation, analytical characterization, and regulatory support to streamline your path to the clinic.

Key Capabilities for mRNA-Based Cancer Immunotherapy

Learn More About Our Approach →

mRNA Modalities for Cancer Immunotherapy

Our platform supports a range of mRNA formats to address diverse therapeutic strategies, from personalized vaccines to systemic immunomodulation.

• Personalized Cancer Vaccine mRNA: mRNA encoding patient-specific tumor neoepitopes identified by NGS, designed to trigger a polyclonal T-cell response against unique cancer mutations.
• Immunomodulator mRNA: mRNA encoding cytokines, chemokines, or co-stimulatory molecules (e.g., IL-12, OX40L) to enhance the tumor microenvironment and boost anti-tumor immunity.
• Bispecific Antibody-Encoding mRNA: mRNA that directs the production of bispecific antibodies, enabling targeted T-cell engagement and tumor cell killing without the need for protein manufacturing.
• Reporter mRNA for Preclinical Studies: mRNA encoding luciferase, GFP, or other reporters for in vivo biodistribution, expression kinetics, and delivery optimization studies in animal models.
• mRNA for CAR-T Cell Engineering: mRNA encoding chimeric antigen receptors (CARs) for transient expression in T cells, enabling non-viral, non-integrating CAR-T cell generation with reduced risk of insertional mutagenesis.

Our mRNA Production Workflow

From gene design to final mRNA product, our streamlined process integrates scalable manufacturing with rigorous quality control.

• Template Design & Synthesis: We design the DNA template based on your target antigen sequence, incorporating optimized untranslated regions (UTRs), codon optimization, and regulatory elements for high expression. The template is synthesized and sequence-verified by Sanger sequencing.
• In Vitro Transcription & Capping: mRNA is transcribed using T7 RNA polymerase with modified NTPs as needed. Co-transcriptional or enzymatic capping is applied to achieve Cap1 or Cap2 structures, followed by poly(A) tail addition and purification.
• Purification & Analytical Quality Control: The mRNA is purified by oligo-dT chromatography or size-exclusion to remove dsRNA, enzymes, and NTPs. QC includes capillary electrophoresis (CE), LC-MS, capping efficiency, poly(A) tail length, and endotoxin testing.
• Formulation & Final Release: For in vivo studies, mRNA can be formulated into lipid nanoparticles (LNPs) using our proprietary or customer-specified lipids. Final product is released with a comprehensive certificate of analysis and stability data.

Project Timeline

Our timeline is designed to match your development needs, with milestones that keep you informed at every stage.

• Sequence Design Review: Collaborative review of target sequence, UTRs, and codon optimization. Final template design approved.
• Template Synthesis & Verification: DNA template synthesized and sequence-verified. Template released for IVT.
• In Vitro Transcription & Capping: mRNA synthesis, capping, and poly(A) tail addition. In-process QC performed.
• Purification & Analytical Release: Final purification, full QC panel, and certificate of analysis generated.
• Final Product Delivery: mRNA shipped in appropriate buffer, with documentation and stability data.

Typical turnaround from sequence to final mRNA product: 6–10 weeks, depending on scale, modifications, and GMP requirements. Expedited timelines are available for urgent programs.

Quality Assurance & Regulatory Compliance

Our mRNA production service operates under a rigorous quality management system designed to meet the requirements of both research and clinical applications. For GMP-grade mRNA, we follow current Good Manufacturing Practice (cGMP) guidelines, with dedicated cleanroom facilities, validated processes, and comprehensive documentation.

Every batch undergoes a standard QC panel that includes: cap efficiency (LC-MS/MS), poly(A) tail length distribution, RNA integrity (capillary electrophoresis), residual DNA and enzymes, endotoxin (LAL), sterility, and appearance. For clinical batches, additional tests such as plasmid copy number, residual solvent, and stability studies are performed.

We have experience supporting regulatory submissions for RNA-based therapeutics in Europe and the US, having worked with the regulatory framework described in the literature for RNA vaccines. Our team can provide the necessary documentation for IND/CTA packages, including process validation, analytical method qualification, and stability protocols.

Why Choose Our mRNA Production Service?

• Integrated Platform: From template design to GMP-grade manufacturing and LNP formulation, we offer a single-source solution that reduces handoffs and accelerates your program.
• Regulatory Experience: Our team has navigated the European regulatory environment for RNA-based vaccines and can support your IND/CTA filing with comprehensive documentation.
• Customization & Flexibility: We tailor capping, poly(A) tail length, modifications, and formulation to your specific therapeutic needs, whether for research, preclinical, or clinical studies.
• Scalable Manufacturing: Our platform scales from small research batches to GMP-grade quantities for clinical trials, with consistent quality across scales.
• Rapid Turnaround: With a streamlined workflow and dedicated project management, we deliver mRNA products in as little as 6–10 weeks, supporting fast-paced development timelines.

Target Cell Types for mRNA Delivery

Our mRNA can be formulated for delivery to a variety of cell types relevant to cancer immunotherapy, enabling both in vitro and in vivo applications.

• Dendritic Cells: mRNA-loaded dendritic cells are a cornerstone of cancer vaccine approaches, where they present tumor antigens to T cells and initiate adaptive immune responses.
• T Cells: mRNA encoding CARs, TCRs, or immunomodulators can be delivered directly to T cells for adoptive cell therapy, enabling transient expression without genomic integration.
• NK Cells: mRNA can be used to engineer NK cells with enhanced tumor recognition and cytotoxicity, offering an off-the-shelf cell therapy alternative.
• Tumor Cell Lines: mRNA delivery to tumor cells in vitro allows for functional studies of antigen expression, immune recognition, and signaling pathways.
• Primary Human Cells: Our mRNA formulations are compatible with primary cells from patients, supporting ex vivo manipulation for personalized cell therapy manufacturing.

Contact Us

Whether you are developing personalized cancer vaccines, neoantigen-based immunotherapies, or CAR-related mRNA programs, our team can support you from mRNA design and synthesis through to GMP-ready manufacturing considerations. Contact us today to discuss your project requirements.